



Investor Service Announcement no. 5/2016

To: NASDAQ Copenhagen A/S

Copenhagen, Denmark, 31 August 2016

**Veloxis Pharmaceuticals A/S Completes Closure of its Hørsholm, Denmark Office**

Veloxis Pharmaceuticals A/S has completed the closure of its office in Hørsholm, Denmark. This closure was previously announced on 9 March 2016 as part of a company restructuring to move all activities to the United States. The company's registered address in Denmark will now be:

Veloxis Pharmaceuticals A/S  
c/o Plesner Advokatfirma  
Amerika Plads 37  
2100 København Ø

**For more information, please contact:**

Veloxis Pharmaceuticals A/S

Craig A. Collard  
President & CEO  
Phone: +1 919 591 3065  
Email: cac@veloxis.com

**About Veloxis Pharmaceuticals**

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit [www.veloxis.com](http://www.veloxis.com).

Veloxis Pharmaceuticals A/S  
c/o Plesner Advokatfirma  
Amerika Plads 37  
2100 København Ø  
CVR no. 26 52 77 67

Investor Service Announcement no. 5/2016